If Curis pursues CUDC-907 in B-cell lymphoma or multiple myeloma, the company would owe a royalty of 2.5X the total amount funded by LLS. http://www.businesswire.com/news/home/20111130005368/en/Curis-Announces-Agreement-Leukemia-Lymphoma-Society-Develop